Multiple sclerosis is one of the most common neurological conditions affecting young adults worldwide, yet the information available to newly diagnosed patients โ and their families โ is often fragmented, overly clinical, or buried in academic language that is inaccessible to non-specialists.
MS Aware was created to bridge that gap. Our mission is to translate the best available clinical and scientific evidence into plain-language resources that empower people โ patients, caregivers, students, and curious minds โ to understand what MS is, how it progresses, what can be done about it, and what the research frontier looks like right now.
We believe that understanding a condition is the first step toward managing it well. We also believe that the boundary between "patient education" and "scientific literacy" should not exist โ which is why MS Aware uniquely combines a compassionate awareness platform with an interactive bioinformatics explorer powered by real, publicly available research data.
"To make the science of MS accessible to everyone โ and to give every person touched by this condition the information they deserve."
โ MS Aware Mission Statement
Evidence-based, plain-language information on every aspect of MS: what it is, how it's diagnosed, treatments available, and how to live well with the condition. Written for patients, families, and anyone who wants to understand.
An interactive dashboard built on real, publicly available gene expression data from MS research. Designed to make molecular biology accessible โ volcano plots, pathway analysis, and gene lookup โ with plain-language explanations throughout.
Every factual claim on this platform is grounded in peer-reviewed literature, clinical guidelines, or data from major MS organisations. All sources are cited and accessible.
Scientific accuracy should not come at the expense of clarity. We use plain English, define technical terms, and always prioritise what the reader actually needs to understand.
We distinguish clearly between what is established, what is emerging, and what is uncertain. We never overstate findings or make diagnostic claims. Limitations are disclosed transparently.
All content is freely available. The bioinformatics explorer uses only publicly available datasets. We believe scientific literacy should not require institutional access or a research background.
If you've just received a diagnosis, this platform helps you understand what MS is, what your options are, and what questions to ask your neurologist.
For loved ones trying to understand what someone with MS is experiencing โ and how to provide meaningful support.
For those exploring MS at an academic level, our bioinformatics section connects awareness content to real data and peer-reviewed research.
Anyone who wants to understand MS โ whether because of a news story, a friend's diagnosis, or pure curiosity โ will find clear, reliable answers here.
What MS Aware is not: This platform is not a substitute for medical care, a diagnostic tool, or a source of personalised medical advice. The information here is educational. For guidance specific to your situation, always consult a qualified neurologist or MS healthcare team.
MS Aware was created as a student-led initiative combining bioinformatics, web development, and public health communication. The project was motivated by a belief that the gap between published MS research and patient-accessible information is too wide โ and that a single, well-designed platform can meaningfully narrow it.
The bioinformatics explorer represents the practical application of computational biology skills to a real clinical problem: using differential gene expression analysis on publicly available datasets to visualise the molecular biology of MS in an interactive, accessible format.
All data used in the bioinformatics section is sourced from NCBI GEO (Gene Expression Omnibus) and is publicly available. Analysis pipelines use industry-standard tools (R/Bioconductor, limma, fgsea). Full methods and citations are available in the Sources & Citations section.
Trusted, compassionate information for people living with multiple sclerosis, their families, and caregivers.
Understand how MS affects the nervous system, who it affects, and why it happens.
RRMS, SPMS, PPMS โ learn the differences between the four main forms.
Disease-modifying therapies, symptom management, and lifestyle approaches.
Practical guidance for daily life, work, relationships, and emotional wellbeing.
Interactive gene expression data from real MS research. Explore what happens at the molecular level.
Not a substitute for medical advice. This website provides general educational information only. Always consult your neurologist or healthcare team about your individual situation.
Multiple sclerosis (MS) is a chronic disease of the central nervous system in which the immune system mistakenly attacks myelin, the protective covering around nerve fibres in the brain and spinal cord.
Symptoms can include fatigue, vision changes, numbness, tingling, weakness, muscle spasms, bladder problems, balance issues, and cognitive changes. Symptoms vary from person to person.
MS is diagnosed through a combination of medical history, neurological examination, MRI findings, and sometimes additional tests such as lumbar puncture or evoked potentials.
There is no cure for MS, but disease-modifying therapies, relapse treatments, symptom management, rehabilitation, and lifestyle support can help reduce disease activity and improve quality of life.
Multiple sclerosis is a chronic disease of the central nervous system โ the brain and spinal cord.
In MS, the immune system mistakenly attacks the protective myelin sheath that surrounds nerve fibres in the brain and spinal cord. This damage disrupts or blocks the nerve signals that control movement, sensation, vision, and many other body functions.
The name "multiple sclerosis" refers to the multiple scars (scleroses) โ also called lesions or plaques โ that form in the nervous system at sites of myelin damage.
Key fact: MS is not contagious, and it is not directly inherited โ though genetic factors can influence your risk.
Acts like insulation around nerve fibres. When damaged, nerve signals slow down, get distorted, or stop entirely.
White blood cells cross the blood-brain barrier and mistakenly attack myelin, causing inflammation and lesion formation.
The brain can repair some myelin damage early in the disease. Over time this repair capacity diminishes.
The exact cause is unknown, but research points to a combination of genetic susceptibility and environmental triggers.
MS is not a one-size-fits-all disease. There are four recognised types, each with a distinct pattern of symptoms and progression.
The most common form of MS. People experience clearly defined relapses during which new or worsening symptoms appear. These are followed by periods of remission โ partial or complete recovery โ where the disease does not progress.
Many people with RRMS transition to SPMS over time. In this phase, disability accumulates more steadily, with or without relapses. The transition is gradual and can be difficult to pinpoint precisely.
Characterised by steady worsening of neurological function from the very beginning, without distinct relapses or remissions. PPMS tends to affect men and women equally and is diagnosed at an older average age than RRMS.
The rarest form of MS. People experience steady neurological decline from onset, but also have clear acute relapses on top of ongoing progression โ unlike PPMS, where progression is smooth.
Note: The MS disease course is not fixed. People may transition between types over time, and your neurologist will monitor changes in your condition at regular appointments.
MS symptoms vary widely from person to person โ no two people experience the disease in quite the same way.
Hover over or tap any highlighted region to learn how multiple sclerosis can affect that part of the body.
Hover over a marker on the body to explore how MS affects that region
Overwhelming tiredness that is not relieved by rest โ one of the most common and disabling MS symptoms.
Optic neuritis (pain with eye movement, blurred or lost vision), double vision, or involuntary eye movements.
Often one of the first symptoms. Can affect the face, body, arms, or legs.
Stiffness, muscle spasms, difficulty walking, or weakness in limbs.
Dizziness, vertigo, unsteady gait, and difficulty with fine motor tasks.
Memory difficulties, slowed thinking, trouble concentrating โ sometimes called "cog fog."
Many MS symptoms are invisible to others, which can make it difficult for people to understand what you are going through.
Heat sensitivity: Many people with MS find that their symptoms temporarily worsen in hot weather, after exercise, or with a fever. This is called Uhthoff's phenomenon and is not a relapse.
A relapse is a new or significantly worsening symptom that lasts more than 24 hours in the absence of fever or infection. Relapses can last days to weeks and recovery can be partial or complete.
There is no single test for MS. Diagnosis involves ruling out other conditions and finding evidence of damage in two or more areas of the nervous system.
A neurologist assesses reflexes, coordination, balance, vision, and sensation to identify signs of nervous system damage.
Magnetic resonance imaging of the brain and spine identifies lesions (areas of myelin damage). This is the most important diagnostic tool for MS.
A sample of cerebrospinal fluid is analysed for oligoclonal bands โ proteins that suggest immune activity in the central nervous system.
These measure how quickly the brain responds to stimuli, and can reveal slowed nerve conduction caused by demyelination.
The internationally accepted diagnostic framework requires evidence of damage in at least two separate areas of the CNS, at two different points in time.
Many conditions can mimic MS symptoms, which is why diagnosis can take time. Common conditions that must be excluded include:
Advocating for yourself: The average time from first symptoms to MS diagnosis is around 5 years. If you feel unheard, it is entirely appropriate to request a referral to a neurologist or seek a second opinion.
There is currently no cure for MS, but there are many effective treatments that reduce relapses, slow progression, and manage symptoms.
Disease-modifying therapies (DMTs) reduce the frequency of relapses and slow the accumulation of new lesions. They are broadly categorised by their route of administration and efficacy level.
Interferons (Avonex, Rebif, Betaseron) and glatiramer acetate. Moderate efficacy, well-established safety profiles.
Dimethyl fumarate, teriflunomide, siponimod, ozanimod. Convenient for many patients; varying efficacy.
Natalizumab (Tysabri), ocrelizumab (Ocrevus), alemtuzumab (Lemtrada). High efficacy, given in clinic.
Regular aerobic and strength exercise reduces fatigue, improves mood, and supports brain health. Aim for consistency over intensity.
A Mediterranean-style diet rich in vegetables, fish, and healthy fats is associated with better MS outcomes. Vitamin D supplementation is widely recommended.
Yoga, mindfulness, and meditation can help manage fatigue, pain, and anxiety in MS.
MS affects every aspect of life โ but with the right knowledge, support, and strategies, many people live full, meaningful lives.
Depression and anxiety are twice as common in people with MS compared to the general population โ and not just as an emotional reaction. MS lesions in certain brain areas directly contribute to mood changes.
It's not just you. Emotional and cognitive changes are recognised neurological symptoms of MS, not signs of weakness. Talk to your MS team โ effective treatment is available.
It can be hard to explain MS to people who have not experienced it. Focus on what it actually feels like for you, rather than textbook definitions. Let people know what kind of support you need โ and what you do not.
Caring for someone with MS can be deeply rewarding and deeply challenging. Carer wellbeing matters โ seek your own support, take breaks, and connect with other caregivers through MS organisations.
"The fatigue was the hardest part for people to understand. I looked fine on the outside. Learning to explain that to my family changed everything."
"I was terrified when I was first diagnosed. Ten years later, I'm still working, still travelling. MS is part of my life, but it doesn't define it."
"Finding an online community of other people with MS made an enormous difference. You realise you are not alone, and there's so much practical wisdom out there."
MS research is advancing rapidly. New treatments, better understanding of disease mechanisms, and potential repair strategies are emerging.
A landmark US military study found that EBV infection dramatically increases MS risk, strengthening the case for an EBV vaccine as a prevention strategy.
2022 ยท Science journal
A new anti-CD20 infusion therapy (Briumvi) joins the high-efficacy treatment options available for relapsing forms of MS.
2023 ยท FDA Approval
Early-phase trials of drugs designed to promote remyelination are showing encouraging signs, opening the door to potential recovery of lost function.
2024 ยท Nature Medicine
Drugs that stimulate the brain's own repair cells (oligodendrocytes) to rebuild the myelin sheath. Several are in Phase 2 trials.
Haematopoietic stem cell transplantation "reboots" the immune system. Increasingly used in aggressive RRMS at specialist centres.
Drugs that protect nerve fibres from damage independent of immune activity, potentially slowing disability independently of DMTs.
Vaccine candidates targeting Epstein-Barr virus are in development with the hope of preventing MS before it starts.
Clinical trials are essential for developing better MS treatments. Participating can give you access to cutting-edge therapies and directly contributes to progress for everyone with MS.
You do not have to face MS alone. A wide range of organisations, communities, and services exist to help you and your family.
The global voice of the MS movement, representing MS societies in over 40 countries. Provides research funding, advocacy, and an atlas of global MS data.
msif.org โThe UK's largest MS charity. Offers helplines, local branches, research funding, and a wealth of information resources.
mssociety.org.uk โProvides comprehensive resources, a helpline, financial assistance, and an MS Navigator service to help connect people with local resources.
nationalmssociety.org โCanada's national MS charity, offering programs, support groups, research funding, and services in both English and French.
mscanada.ca โMS-specific forums such as MS-UK's online community, Reddit's r/MultipleSclerosis, and MS Society discussion boards.
Face-to-face peer support through MS society branches. Use your national MS charity's branch finder to locate groups near you.
Be matched with someone who has similar MS experiences. Many MS societies offer these one-to-one peer support programmes.
Every claim on this platform is grounded in evidence. Below you will find the peer-reviewed papers, clinical guidelines, and datasets that underpin every section of MS Aware.
How to use this page: Citations are organised by website section. Each entry includes authors, title, journal, year, and where available, a DOI or direct link. For the bioinformatics section, dataset accession numbers and analysis tools are also listed.
Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92(10):e1029โe1040.
Source for global and US MS prevalence figures. Used in: Home page statistics, What is MS section.
DOI: 10.1212/WNL.0000000000007035 โMS International Federation. Atlas of MS 2020: Mapping multiple sclerosis around the world โ key epidemiology findings. MSIF. 2020.
Primary source for global MS prevalence (2.9 million), incidence, and geographic distribution. Used in: Home statistics, What is MS section.
msif.org/atlas โCompston A, Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502โ1517.
Landmark comprehensive review of MS pathophysiology, immunology, genetics, and treatment. One of the most widely cited MS overview papers. Used in: What is MS, Types of MS, Symptoms sections.
DOI: 10.1016/S0140-6736(08)61620-7 โReich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New England Journal of Medicine. 2018;378(2):169โ180.
Current state-of-the-art review of MS mechanisms, diagnosis, and treatment published in one of the highest-impact medical journals. Used in: What is MS, Diagnosis, Treatment sections.
DOI: 10.1056/NEJMra1401483 โNoseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New England Journal of Medicine. 2000;343(13):938โ952.
Foundational NEJM review covering the full spectrum of MS biology and care. Used in: What is MS, pathophysiology explanations.
DOI: 10.1056/NEJM200009283431307 โFilippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nature Reviews Disease Primers. 2018;4(1):43.
Comprehensive Nature Reviews primer covering epidemiology, mechanism, imaging, biomarkers, and treatment. Used in: What is MS, Myelin biology, immune mechanisms.
DOI: 10.1038/s41572-018-0041-4 โLublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014;83(3):278โ286.
The definitive paper establishing the revised classification of MS phenotypes (RRMS, SPMS, PPMS, PRMS). The current internationally accepted framework used by neurologists worldwide. Used in: Types of MS section, all disease course descriptions.
DOI: 10.1212/WNL.0000000000000560 โWeinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. Brain. 1989;112(1):133โ146.
Classic longitudinal natural history study. Source for RRMS-to-SPMS transition statistics (~50% at 10 years). Used in: Types of MS, SPMS description.
DOI: 10.1093/brain/112.1.133 โAmato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. Journal of the Neurological Sciences. 2006;245(1โ2):41โ46.
Source for the statistic that up to 65% of people with MS experience cognitive changes. Used in: Symptoms section, Brain & CNS panel.
DOI: 10.1016/j.jns.2005.08.019 โKrupp LB. Fatigue in multiple sclerosis: Definition, pathophysiology and treatment. CNS Drugs. 2003;17(4):225โ234.
Key reference on MS fatigue โ one of the most disabling symptoms. Used in: Symptoms section, fatigue card.
DOI: 10.2165/00023210-200317040-00002 โKalb R, Beier M, Benedict RH, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Multiple Sclerosis Journal. 2018;24(13):1665โ1680.
Clinical guidance on cognitive assessment in MS. Used in: Symptoms, cognitive changes description.
DOI: 10.1177/1352458518803785 โFowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2009;80(5):470โ477.
Source for the statistic that bladder problems affect around 80% of people with MS at some point. Used in: Symptoms, bladder & bowel panel.
DOI: 10.1136/jnnp.2008.159178 โFrohman TC, Davis SL, Frohman EM. Uhthoff's phenomenon in MS โ clinical features and pathophysiology. Nature Reviews Neurology. 2013;9(9):535โ540.
Definitive review of Uhthoff's phenomenon (heat-induced symptom worsening). Used in: Symptoms section, heat sensitivity callout.
DOI: 10.1038/nrneurol.2013.136 โThompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162โ173.
The current and definitive diagnostic framework for MS. The McDonald Criteria are the internationally accepted standard. Used in: Diagnosis section, McDonald Criteria step.
DOI: 10.1016/S1474-4422(17)30470-2 โBrownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: Progress and challenges. The Lancet. 2017;389(10076):1336โ1346.
Source for the ~5 year average diagnostic delay statistic and discussion of differential diagnosis. Used in: Diagnosis section, advocacy callout.
DOI: 10.1016/S0140-6736(16)30959-X โPolman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292โ302.
The 2010 McDonald Criteria revision โ still frequently referenced in clinical practice. Used in: Diagnosis section background.
DOI: 10.1002/ana.22366 โMontalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal. 2018;24(2):96โ120.
The European evidence-based clinical guidelines for DMT use in MS. Basis for treatment pathway descriptions. Used in: Treatment section, all DMT categories.
DOI: 10.1177/1352458517751049 โHauser SL, Cree BAC. Treatment of multiple sclerosis: A review. The American Journal of Medicine. 2020;133(12):1380โ1390.
Comprehensive, current review of all MS treatment categories including interferons, glatiramer, oral agents, and high-efficacy infusions. Used in: Treatment section.
DOI: 10.1016/j.amjmed.2020.05.049 โComi G, Bar-Or A, Lassmann H, et al. Role of B cells in multiple sclerosis and related disorders. Annals of Neurology. 2021;89(1):13โ23.
Scientific basis for anti-CD20 therapies (ocrelizumab, ublituximab). Used in: Treatment section, infusion DMTs.
DOI: 10.1002/ana.25927 โMotl RW, Sandroff BM, Kwakkel G, et al. Exercise in patients with multiple sclerosis. The Lancet Neurology. 2017;16(10):848โ856.
Evidence base for exercise benefits in MS โ fatigue reduction, mood, strength. Used in: Treatment, lifestyle section; Living with MS.
DOI: 10.1016/S1474-4422(17)30281-8 โLassmann H. Multiple sclerosis pathology. Cold Spring Harbor Perspectives in Medicine. 2018;8(3):a028936.
Authoritative review of MS lesion pathology โ the biological basis for relapse management with steroids. Used in: Treatment, relapse management section.
DOI: 10.1101/cshperspect.a028936 โSiegert RJ, Abernethy DA. Depression in multiple sclerosis: A review. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(4):469โ475.
Source for the statistic that depression and anxiety are twice as common in MS as in the general population, and that they have neurological (not purely emotional) causes. Used in: Living with MS, mental health section.
DOI: 10.1136/jnnp.2004.054635 โStrober LB. Quality of life and psychological well-being in the early stages of multiple sclerosis (MS): Findings from a longitudinal study. Psychological Health Medicine. 2018;23(5):503โ508.
Longitudinal data on wellbeing outcomes in MS. Used in: Living with MS.
DOI: 10.1080/13548506.2017.1338736 โBjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296โ301.
Landmark US military cohort study (10 million service members, 20 years follow-up) confirming EBV as a major triggering factor for MS. Used in: Research & News, EBV card. This is one of the most important MS papers published in the last decade.
DOI: 10.1126/science.abf4832 โLubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis: From basic science to clinical translation. The Lancet Neurology. 2020;19(8):678โ688.
State-of-the-art review of remyelination biology and emerging repair strategies including oligodendrocyte precursor cell therapeutics. Used in: Research, remyelination card and pipeline.
DOI: 10.1016/S1474-4422(20)30140-X โUS FDA. FDA approves new treatment for adults with relapsing forms of multiple sclerosis (Ublituximab/Briumvi). FDA News Release. December 28, 2022.
Regulatory approval notice for ublituximab. Used in: Research & News, treatment approval card.
fda.gov โBaecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: Mechanisms and immunotherapy. Neuron. 2018;97(4):742โ768.
Comprehensive review of MS immunopathology and the rationale for current and emerging DMTs including HSCT. Used in: Research, stem cell section; Treatment, mechanism explanations.
DOI: 10.1016/j.neuron.2018.01.021 โGreenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: Entering an era. Annals of Neurology. 2018;83(1):13โ26.
Scientific rationale for B-cell depletion therapies โ the fastest growing DMT class. Used in: Treatment, infusion DMTs (ocrelizumab/ublituximab).
DOI: 10.1002/ana.25098 โAbout the bioinformatics data: The MS Data Explorer is built on one publicly available dataset from NCBI GEO. All analysis was performed using peer-reviewed, open-source bioinformatics tools. No proprietary data was used. The dataset and all tools are freely accessible to anyone.
Kemppinen A, Sawcer S, Compston A. Whole genome association studies in multiple sclerosis: Why do they work and what do they tell us? Journal of Autoimmunity. 2011;37(2):97โ106. Dataset: GEO Accession GSE17048.
Primary dataset for the MS Data Explorer. Whole blood microarray (Affymetrix HGU133Plus2), 95 samples: 55 MS patients (RRMS, SPMS, PPMS) and 40 healthy controls. Deposited in NCBI Gene Expression Omnibus. Accessed April 2025.
NCBI GEO: GSE17048 โBarrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: Archive for functional genomics data sets โ update. Nucleic Acids Research. 2013;41(D1):D991โD995.
The primary citation for NCBI Gene Expression Omnibus (GEO), the public repository from which GSE17048 was obtained. Used in: Data Explorer, Methods page.
DOI: 10.1093/nar/gks1193 โRitchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47.
The primary citation for the limma R/Bioconductor package used for differential expression analysis in the Data Explorer pipeline. limma with eBayes moderation is the gold standard for microarray DE analysis.
DOI: 10.1093/nar/gkv007 โIrizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research. 2003;31(4):e15.
The primary citation for RMA (Robust Multi-Array Average) normalization โ the method used to normalise the Affymetrix microarray data in the pipeline.
DOI: 10.1093/nar/gng015 โKorotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv. 2016. (fgsea R package.)
Citation for the fgsea R package used for pathway enrichment analysis using Hallmark and KEGG gene sets.
DOI: 10.1101/060012 โLiberzon A, Birger C, Thorvaldsdรณttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) Hallmark gene set collection. Cell Systems. 2015;1(6):417โ425.
Citation for the MSigDB Hallmark gene sets used in pathway analysis. These curated sets represent coherent biological states relevant to disease biology.
DOI: 10.1016/j.cels.2015.12.004 โSmyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004;3(1):Article 3.
The foundational methodological paper for limma's empirical Bayes approach. Provides the statistical framework for the differential expression analysis in the Data Explorer.
DOI: 10.2202/1544-6115.1027 โOttoboni L, Frohlich IY, Lee M, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013;81(22):1891โ1899.
Comabella M, Lรผnemann JD, Rรญo J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-ฮฒ in multiple sclerosis. Brain. 2009;132(12):3353โ3365.
Validation references: These papers confirm that interferon-stimulated genes (IFIT1, OAS1, MX1) are reproducibly upregulated in MS whole blood โ providing the biological benchmark against which the Data Explorer's results are validated. If these genes are among the top upregulated in the dashboard, the analysis is working correctly.
Brain 2009: DOI 10.1093/brain/awp294 โAll clinical content on this platform was developed by reviewing the primary literature listed above, supplemented by guidance from major MS organisations (MS Society UK, National MS Society USA, MSIF, MS Canada). Where statistics or clinical facts are presented, they are sourced from the specific papers cited in this section.
Content on patient experiences (story cards) is representative and anonymised โ drawn from publicly available accounts in MS Society resources and clinical literature on patient experience, not from identified individuals.
If you identify any factual error or outdated information, please note that MS research moves rapidly and guidance is periodically updated. Always verify clinical information with your healthcare team or the original source.
Last reviewed: April 2025. This platform does not provide medical advice, diagnosis, or treatment recommendations. All information is for educational purposes only.
GSE17048 is a publicly available whole-blood microarray dataset deposited in NCBI Gene Expression Omnibus. It contains samples from three MS subtypes and healthy controls, profiled using Affymetrix HG-U133Plus2 arrays covering over 20,000 human genes.
Publication: Kemppinen et al. (2011) Journal of Autoimmunity. GEO: GSE17048.
Analysis: RMA normalisation โ limma linear model โ eBayes moderation โ Benjamini-Hochberg FDR correction. Thresholds: adj.p < 0.05 AND |logFC| > 0.5.
Number of samples per disease category in GSE17048
| Parameter | Value |
|---|---|
| Array platform | Affymetrix HG-U133Plus2 |
| Tissue source | Whole peripheral blood |
| Normalisation | RMA (Robust Multi-Array Average) |
| DE method | limma linear models + empirical Bayes (eBayes) |
| Multiple testing correction | Benjamini-Hochberg FDR |
| Significance thresholds | adj. p-value < 0.05 AND |logFC| > 0.5 |
| Primary comparison | All MS (n=55) vs Healthy Control (n=40) |